T. Rowe Price reports 157,965 shares (0.2%) in Replimune
Replimune Group amended a Schedule 13G/A to report that T. Rowe Price Associates, Inc. beneficially owns 157,965 shares of Replimune common stock, representing 0.2% of the class.
Rhea-AI Filing Summary
Replimune Group amended a Schedule 13G/A to report that T. Rowe Price Associates, Inc. beneficially owns 157,965 shares of Replimune common stock, representing 0.2% of the class. The filing states T. Rowe Price has sole voting power over 152,716 shares and sole dispositive power over 157,965 shares. The filer affirms this ownership disclosure while also denying beneficial ownership in a boilerplate statement.
Positive
- None.
Negative
- None.
Insights
Small passive stake reported by T. Rowe Price in Replimune.
The amendment records 157,965 shares (0.2%) of common stock with sole voting and dispositive powers noted. This is a routine ownership disclosure under Schedule 13G/A for an institutional investor.
Stake size and filing type suggest passive investment status; subsequent filings would show any material changes in holdings or voting intent.
Key Figures
Key Terms
Schedule 13G/A regulatory
Beneficially owned regulatory
Sole dispositive power regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did T. Rowe Price report for REPL in the Schedule 13G/A?
Does the Schedule 13G/A indicate T. Rowe Price controls Replimune?
What is the significance of the 0.2% ownership reported for REPL?
Who signed the Schedule 13G/A for T. Rowe Price and when?
What does the filer mean by denying beneficial ownership in the filing?
AI-generated analysis. How Rhea-AI works. Not financial advice.